louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06861985: Effects of HFMH-EMS on Ocular Artery Circulation
Official title: The Effects of High-Frequency Multiband Harmonic Electromagnetic Stimulation (HFMH-EMS) on Ocular Artery Circulation After Prolonged Smartphone Usage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ocular Surface Disease
Central Retinal Artery Occlusion
Lead sponsor: Chung Shan Medical University
Sponsor class: OTHER
First posted: 2025-03-06
Enrollment: 43
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is a randomized double-blind controlled trial. All participants who meet the inclusion criteria are randomly assigned to either the "high-frequency multi-band harmonic electromagnetic stimulation device group" as the experimental group or the "placebo device group" as the control group.
Primary purpose: TREATMENT

Brief summary: Investigated the effects of high-frequency multi-band harmonic electromagnetic stimulation on ophthalmic and central retinal artery circulation.

Detailed description: This study investigated the effects of prolonged smartphone usage for over 90 minutes on ophthalmic and central retinal artery circulation before and after smartphone use and compared the effects with versus without intervention by high-frequency multi-band harmonic electromagnetic stimulation.

Eligibility criteria: Inclusion Criteria:

* 20 to 65 years old

Exclusion Criteria:

* hypertension
* diabetes
* heart disease
* eye-related diseases

Primary outcomes:
measure: Peak Systolic Velocity (PSV)
timeFrame: At the first visit and after 90 minutes usage of device.
measure: End Diastolic Velocity (EDV)
timeFrame: At the first visit and after 90 minutes usage of device.
measure: Central Retinal Artery (CRA)
timeFrame: At the first visit and after 90 minutes usage of device.
Secondary outcomes:
Other outcomes:
Locations:
city: Hsinchu
country: Taiwan
facility: National Central University
Study officials:
References:
Clinical trial NCT01049685: Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy
Official title: Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: HIV Infections
Keywords: HIV
Antiretroviral Therapy, Highly Active
Efavirenz
Lopinavir
Comparative Effectiveness Research
Treatment Naive
Lead sponsor: UPECLIN HC FM Botucatu Unesp
Sponsor class: OTHER
First posted: 2010-01-14
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary endpoint: virological success (HIV RNA \<50 copies/mL) in the first six months and at the end of the study.

Detailed description: Background: Either LPV/r or EFZ plus a two nucleoside reverse-transcriptase inhibitors (NRTIs) are recommended by the current guidelines all around the world as the main background drugs for initial therapy of human immunodeficiency virus type 1 (HIV-1) infection. This indication is based in results of clinical trials, but patients who participate in these studies usually are greatly motivated to continue their prescribed regimen, and can be different from the "real life". Therefore, clinical practice often cannot reproduce published results.

Methods: A retrospective longitudinal cohort study was performed with 36 naïve-treatment patients, who started therapy with LPV/r or EFZ, with follow-up of 36 months. The primary endpoint was virological success (HIV RNA \<50 copies/mL) in the first six months and at the end of the study. Effectiveness was examined comparing time to virological failure and CD4 recovery.

Eligibility criteria: Inclusion Criteria:

* HIV-1 infected naive-treatment patients

Exclusion Criteria:

* use of Anti-Retroviral Agents in the past

Primary outcomes:
measure: Maintenance HIV RNA <50 copies/mL at the end oh 36 months
timeFrame: 36 months
Secondary outcomes:
measure: Achieve HIV RNA <50 copies/mL at the first 6 months
timeFrame: 6 months
Other outcomes:
Locations:
city: Botucatu
country: Brazil
facility: SAE e Hospital Dia Domingos Alves Meira
state: SP
Study officials:
affiliation: Botucatu School of Medicine
name: Alexandre N Barbosa, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05556785: Association of Epicardial Adipose Tissue Volume Axnd Radiodensity With Coronary Artery Calcification in Patients With HFpEF
Official title: Association of Epicardial Adipose Tissue Volume Axnd Radiodensity With Coronary Artery Calcification in Patients With HFpEF
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure With Preserved Ejection Fraction
Lead sponsor: Chongqing Medical University
Sponsor class: OTHER
First posted: 2022-09-27
Enrollment: 200
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients were diagnosed with HFpEF and admitted to the Cardiology Department of the First Affiliated Hospital of Chongqing Medical University.

Brief summary: Recruiting patients who were diagnosed with HFpEF. Using Non-contrast CT to measure the total Agatston coronary artery calcification score, epicardial adipose tissue volume and attenuation. Analysing the correlation between them.

Detailed description: The study enrolled patients who were diagnosed with HFpEF and admitted to the Cardiology Department of the First Affiliated Hospital of Chongqing Medical University. Using Non-contrast CT to measure the total Agatston coronary artery calcification score, epicardial adipose tissue volume and attenuation. Finally, analysing the correlation between them.

Eligibility criteria: Inclusion Criteria:

* Typical symptoms and signs of heart failure
* Left ventricular ejection fraction≥50%
* HFA-PEFF score≥5

Exclusion Criteria:

* severe myocarditis, malignant tumors, liver or renal insufficiency, severe valvular heart disease, and received a bypass surgery or other open-heart surgery

Primary outcomes:
measure: Association of epicardial adipose tissue volume axnd radiodensity with coronary artery calcification in Patients with HFpEF
timeFrame: 2022.09
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
Study officials:
References:
Clinical trial NCT03796585: Assessing Barriers and Increasing Use of Immunization Registries in Pharmacies
Official title: Assessing Barriers and Increasing Use of Immunization Registries in Pharmacies: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Immunization
Lead sponsor: Auburn University
Sponsor class: OTHER
Collaborators: name: Agency for Healthcare Research and Quality (AHRQ)
First posted: 2019-01-08
Enrollment: 52
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to identify barriers to utilization of immunization registries within a pharmacy context and tailor the information into a novel immunization registry training program.

Detailed description: The purpose of this study is to identify barriers to utilization of immunization registries within a pharmacy context and tailor the information learned about barriers into a novel immunization registry training program with strategies specific to individual subsets of pharmacies, independent pharmacies in rural areas. Doing so will help achieve the long-term goal which is to increase the use of immunization registries in community pharmacies in Alabama.

The specific aims are to

1. identify barriers and best practices of immunization registry implementation,
2. use a participatory design approach to develop an immunization registry training program, and
3. disseminate and assess the impact of the immunization registry training program among community pharmacies' registry participation rates.

The impact of the training program on registry participation rates will be assessed using a randomized controlled trial design comparing Alabama community pharmacies' registry data as well as intention to participate.

Eligibility criteria: Inclusion Criteria:

* not currently enrolled in ImmPRINT
* currently provide at least one type of vaccination in addition to influenza
* independently owned
* agree to provide requested data for assessment

Exclusion Criteria:

-

Primary outcomes:
measure: Number of pharmacies enrolled in the Alabama Immunization Registry
timeFrame: 3 months
Secondary outcomes:
measure: Level of Immunization Registry Participation
timeFrame: 3 months
measure: Change in awareness
timeFrame: 1 month and 3 months
measure: Change in knowledge
timeFrame: 1 month and 3 months
measure: Change in attitudes
timeFrame: 1 month and 3 months
measure: Change in intention to enroll in immunization registry
timeFrame: 1 month and 3 months
measure: Change in Implementation Factors
timeFrame: 3 months
Other outcomes:
Locations:
city: Auburn
country: United States
facility: Auburn University
state: Alabama
Study officials:
References:
citation: Hastings TJ, Ha D, Fox BI, Qian J, Lakin J, Westrick SC. Increasing use of immunization information systems for routine vaccinations in independent community pharmacies: A randomized controlled trial. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1270-1279.e2. doi: 10.1016/j.japh.2022.02.010. Epub 2022 Feb 19.
Clinical trial NCT05444985: Postoperative Analgesic Effects of Bilateral External Oblique Intercostal Block in Laparoscopic Cholecystectomy Surgery
Official title: Post-operative Analgesic Effects of Bilateral External Oblique Intercostal Block in Laparoscopic Cholecystectomy Surgeries.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Analgesia
Pain, Postoperative
Keywords: External oblique intercostal block
Pain management
Lead sponsor: Samsun University
Sponsor class: OTHER
First posted: 2022-07-06
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: One interventional group and one control group.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of our study is to reduce postoperative pain by performing external oblique intercostal block in L/S cholecystectomy surgeries. Our main goal is to provide well managed post-operative analgesia.

Detailed description: The patients will be divided into two groups and general anesthesia will be applied to all of them. There will be no regional anesthetic technique to be performed, on the other hand, external oblique intercostal nerve block will be applied to patients in the other group before the patients are extubated. Study randomization is done with computer-generated randomization codes (computer-generated) by a physician who will not participate in patient follow-up. Interfascial plane block (external oblique intercostal block) will be given to the anesthesiologist in a sealed envelope by an independent assistant staff outside the study, the patient will not know which block is applied. The anesthetist who made the block will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be performed by another anesthetist blinded to the study.

For the standardization, the block procedure will be performed by an experienced anesthesiologist who has performed at least 20 previous successful and uncomplicated procedures.

Eligibility criteria: Inclusion Criteria:

* BMI \< 35 kg/m²
* Patients with ASA scores I and II

Exclusion Criteria:

* Patients who do not want to be included in the study
* Psychiatric and neurological disease with blurred consciousness
* Patients with ASA \> 3
* BMI \> 35 kg/m²
* Abnormality in coagulation parameters
* History of allergy to local anesthetic drugs
* Infection at the injection site

Primary outcomes:
measure: Postoperative opioid consumption
timeFrame: 24 hours
Secondary outcomes:
measure: NRS scores
timeFrame: At 1,3, 6, 12, 18, 24 hours
measure: Quality of recovery
timeFrame: 24 hours
measure: Nausea and vomiting
timeFrame: At 1,3, 6, 12, 18, 24 hours
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Samsun University
Study officials:
affiliation: Samsun University
name: Hatice Kusderci, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04172285: Physical Activity Program for Counteracting Sarcopenia
Official title: Effects of an Home-base Physical Activity Program for Counteracting Sarcopenia in Elderly: a Randomized-controlled Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sarcopenia
Lead sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Sponsor class: OTHER
First posted: 2019-11-21
Enrollment: 16
Sex: ALL
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sarcopenia is a pathophysiological process associated with aging and some metabolic conditions characterized by progressive muscle tissue loss, which may lead to loss of strangth and performance and increase risk of falls and fractures, physical disability and premature death. Therefore, it is necessary to identify personalized programs of physical activity and supplementation for elderly population in order to improve their physical functions, muscle strengh and body composition.

With the present project we aime to assess the effect of a feasible home-based exercise program coupled with food supplementation to improve muscle strength, muscle volume and muscle physical performance potentially associated with sarcopenia in elderly people.


Eligibility criteria: Inclusion Criteria:

* Sedentary lifestyle.
* Cognitively intact.
* Autonomous walking.
* Acceptance of informed consent.

Exclusion Criteria:

* Body mass index lower than 18.5 and uppen than 40 kg/m2.
* History of cancer.
* Pacemaker user.
* History of epileptic episodes.
* Endocrine-metabolic, neurological, muscular and ortopedic pathologies that affect movement functions.
* Bone fractures that influence movement functions.
* Smoking.
* Surgical treatments in the prior 6 months.
* Use of antieptilectics, glucocorticoids, rhGH and testosterone.
* Hepatic and muscular pathologies

Primary outcomes:
measure: Lower limb strength
timeFrame: Baseline and Week 24
Secondary outcomes:
measure: Body composition
timeFrame: Baseline and Week 24
measure: Quantify thigh cross sectional area
timeFrame: Baseline and Week 24
measure: Maximum isometric force that a hand can squeeze
timeFrame: Baseline and Week 24
measure: Maximal Isometric Strength of Knee flexors and extensors
timeFrame: Baseline AND Week 24
measure: Dynamic balance and gait deficits
timeFrame: Baseline and Week 24
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS Istituto Ortopedico Galeazzi
Study officials:
References:
Clinical trial NCT00416585: Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne
Official title: Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acne
Keywords: acne
isotretinoin
calcium. vitamin D
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-12-28
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne

Detailed description: few studies has been done of serum levels Ca, P, PTH and vitamin D metabolites in patients receiving isotretinoin .In this study we measured serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne in 30 patients . the patients had no kown skeletal, endocrine ,renal and gastrointestinal disorders.

Eligibility criteria: Inclusion Criteria:

* sever acne

Exclusion Criteria:

* renal disorders
* gastrointestinal disorders
* skeletal disorders
* endocrine disorders
* drugs such as glucocorticoids , thiazide diuretics, mineral multivitamins, anti acids, tetracyclines

Primary outcomes:
measure: serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray before the treatment
Secondary outcomes:
measure: serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray after the treatment
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Shaheed Beheshti Medical University, Skin research center
Study officials:
affiliation: Skin Research Center
name: parviz toossi, md
role: STUDY_CHAIR
affiliation: Skin Research Center
name: Hamideh Moravvej, md
role: PRINCIPAL_INVESTIGATOR
affiliation: Skin Research Center
name: Nahid Mohtasham, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00387985: Bioequivalence Study in Healthy Volunteers
Official title: An Open-label, Single-dose, Randomized, 2-period Crossover, Bioequivalence Study Between the Current Formulation and the New Formulation of MOA-728 Administered Subcutaneously in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
First posted: 2006-10-13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Primary: To determine the bioequivalence between the new formulation and the current formulation of the investigational drug, MOA-728.


Eligibility criteria: Inclusion Criteria:

* Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).

Primary outcomes:
measure: bioequivalence
Secondary outcomes:
Other outcomes:
Locations:
city: Willingboro
country: United States
state: New Jersey
Study officials:
affiliation: Bausch Health Americas, Inc.
name: Jeff Cohn
role: STUDY_DIRECTOR
References:
Clinical trial NCT01726985: Model for Heart Failure ExAcerbation Reduction Trial
Official title: Model for Heart Failure ExAcerbation Reduction Trial - "Model HEART"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute on Chronic Heart Failure
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2012-11-15
Enrollment: 230
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients aged 18 and over hospitalized at Cleveland Clinic Florida with diagnosis of CHF.

Brief summary: Heart failure is the leading cause of hospitalizations and readmissions in the United States and is a tremendous economic strain on our healthcare system. There is currently, based on national averages, a 30% readmission rate and 10% mortality rate within 3 months of being hospitalized for heart failure. Retrospective studies have shown benefit to using biomarkers such as BNP to guide inpatient heart failure management. Our own CCF retrospective study showed that decreasing NT-ProBNP by 23%, making patients fluid negative by more than 1.3L, and discharging patients with serum sodium above 135 reduces readmission rates significantly. The purpose of this study is to prospectively use the above mentioned goals in the treatment of heart failure in order to reduce heart failure readmission and mortality rates.

Detailed description: All HF patients admitted to CCF will receive a short consent form. The study will enroll patients for one year. Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the 3 (above mentioned) criteria are met. Physicians will receive a copy of consent forms, educational bulletins, and discharge forms (as described in the Physician Education document which is attached to this application). Log-rank test will be used to compare groups. Chi-Square will be used to compare prospective patients with retrospective controls (obtained in 2010).

Eligibility criteria: Inclusion Criteria:

* Must have either Acute on Chronic Heart Failure or Chronic Heart Failure regardless of presenting/primary complaint

To fulfill CHF Dx, MUST have 2+ of the following:

* Clinical: Dyspnea, orthopnea, PND, edema, S3, rales, improve w diuretics
* Radiographic: Pulm venous congestion, pleural effs, cardiomegaly
* Lab: NT pro BNP \> 1000

Exclusion Criteria:

* None

Primary outcomes:
measure: Hospital Readmission for CHF
timeFrame: up to 1 year
Secondary outcomes:
measure: CHF Mortality
timeFrame: 90 days, 180 days, 1 yr
Other outcomes:
Locations:
city: Weston
country: United States
facility: Cleveland Clinic Florida
state: Florida
Study officials:
affiliation: Cleveland Clinic Florida
name: Marlow Hernandez
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01564485: Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome
Official title: Role of Cardiac CT in Risk Factor Control in Asymptomatic Patients With Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Metabolic Syndrome
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2012-03-27
Enrollment: 193
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study looked at the role of cardiac CT in improving risk factor control in those with diabetes.

Detailed description: This study examined whether doing a cardiac screening test, the cardiac CT, would result in patients paying more attention to controlling their risk factors.

Eligibility criteria: Inclusion Criteria:

* Age \> 18
* Diabetes
* Metabolic Syndrome

Exclusion Criteria:

* Symptoms of heart disease
* Heart Disease
* Renal disease

Primary outcomes:
measure: Systolic BP Pressure
timeFrame: Five year follow up
Secondary outcomes:
Other outcomes:
measure: Change in Treatment by PCP
timeFrame: 2 years
Locations:
city: Orange
country: United States
facility: University of California, Irvine Medical Center
state: California
Study officials:
affiliation: University of California, Irvine
name: Shaista Malik, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: